MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Analyst Ratings
USA - NASDAQ:MDGL - US5588681057 - Common Stock
435.78 USD
+14.28 (+3.39%)
435.78 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 82% to MDGL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 488.72. This target is 12.15% above the current price.
MDGL was analyzed by 22 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about MDGL.
In the previous month the buy percentage consensus was at a similar level.
MDGL was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-15 | Truist Securities | Initiate | Buy |
| 2025-10-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-10-10 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-09-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-26 | TD Cowen | Maintains | Buy -> Buy |
| 2025-08-20 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-12 | UBS | Maintains | Buy -> Buy |
| 2025-08-06 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-02 | B. Riley Securities | Reiterate | Buy -> Buy |
| 2025-05-02 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-04-24 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-27 | Citigroup | Maintains | Buy -> Buy |
| 2025-02-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-10 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-20 | Cantor Fitzgerald | Reiterate | Neutral |
| 2024-11-05 | B. Riley Securities | Maintains | Neutral -> Neutral |
| 2024-11-01 | UBS | Maintains | Buy -> Buy |
| 2024-10-23 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-10-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-11 | Cantor Fitzgerald | Reiterate | Neutral |
| 2024-08-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-08-08 | Citigroup | Maintains | Buy -> Buy |
| 2024-07-23 | Cantor Fitzgerald | Reiterate | Neutral |
| 2024-07-16 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-06-28 | Cantor Fitzgerald | Initiate | Neutral |
| 2024-06-11 | Wolfe Research | Initiate | Outperform |
| 2024-05-10 | B. Riley Securities | Maintains | Neutral -> Neutral |
MADRIGAL PHARMACEUTICALS INC / MDGL FAQ
What is the average price target for MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
22 analysts have analysed MDGL and the average price target is 488.72 USD. This implies a price increase of 12.15% is expected in the next year compared to the current price of 435.78.
What is the consensus rating for MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
The consensus rating for MADRIGAL PHARMACEUTICALS INC (MDGL) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
The number of analysts covering MADRIGAL PHARMACEUTICALS INC (MDGL) is 22.